Caplin Point Laboratories Limited

NSE: CAPLIPOINT

Healthcare Healthcare

₹2,571

+1.63%EOD · 19 Aug

Caplin Point Laboratories Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹19,543 Cr

52W Range

₹2699 / ₹1500

Volume

77K

50.5% delivery

1Y Return

+15.8%

P/E Ratio

28.4

P/B Ratio

5.4

ROE

19.9%

Debt / Equity

0.13

Peers in Healthcare

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Caplin Point Laboratories Limited(this stock)	₹2,571	₹19,543 Cr	28.4	5.4	19.9%	0.32%
Divi's Laboratories LimitedDIVISLAB	₹8,560	₹2.27 L Cr	87.5	13.4	16.2%	0.35%
Torrent Pharmaceuticals LimitedTORNTPHARM	₹5,013	₹1.91 L Cr	76.9	19.5	17.0%	0.79%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP	₹8,750	₹1.26 L Cr	61.4	13.5	21.5%	0.23%
Zydus Lifesciences LimitedZYDUSLIFE	₹1,104.5	₹1.10 L Cr	25.3	4.2	18.3%	0.09%
Mankind Pharma LimitedMANKIND	₹2,394	₹98,871 Cr	49.0	6.1	12.4%	0.08%
Laurus Labs LimitedLAURUSLABS	₹1,801.8	₹97,353 Cr	88.6	18.2	17.7%	0.13%
Max Healthcare Institute LimitedMAXHEALTH	₹997	₹97,036 Cr	67.7	9.1	14.3%	0.20%
Aurobindo Pharma LimitedAUROPHARMA	₹1,624.5	₹93,470 Cr	25.3	2.5	9.9%	0.24%

Technical Indicators

Full analysis · objective math, not advice

Returns

+1.6%

+2.9%

+4.2%

+26.5%

+55.5%

+15.8%

Weinstein Stage

Stage 2 — Advancing (uptrend)

RSI (14)

51 Neutral

Trend Template

7/7strong

RS vs Nifty (3M)

+19.7pp

Moving Averages (price vs MA)

20-DMA

₹2550

above

50-DMA

₹2560

above

150-DMA

₹2090

above

200-DMA

₹2034

above

From 52W High

-4.7%

From 52W Low

+71.4%

Support (20D)

₹2383

Resistance (20D)

₹2675

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.